Business
Research collaboration update
Research collaboration update.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 3130G N4 Pharma PLC 05 November 2018 \n\n05 November 2018\n \nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\n \nResearch collaboration update\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, today provides an update on its collaboration with MedImmune, following the conclusion of the Innovate UK feasibility grant announced on 2 February 2018.\n \nThe grant was provided by Innovate UK to co-fund a collaborative project with MedImmune to explore the manufacture of a prototype nanomedicine using N4 Pharma's Nuvec® system. The initial term of the project with MedImmune was a period of nine months ending 31 October 2018. In total, the Company will receive £63,000 from Innovate UK. \n \nThe Company is pleased to announce that MedImmune has confirmed its committment to investigating non-lipid nanoparticle technologies for mRNA and pDNA delivery and its intention to continue to work with N4 Pharma to conduct further ongoing research with a view to agreeing terms for co-development of an optimised version of Nuvec® under an appropriate collaboration agreement.\n \n \nNigel Theobald, CEO of N4 Pharma commented: \n \n\"The grant has allowed us to take a positive step forward with our Nuvec® delivery system and we are very grateful for the support provided by Innovate UK and MedImmune.\n \n\"We are delighted that MedImmune is continuing to work with N4 Pharma to evaluate the potential of our Nuvec® system. MedImmune is able to provide considerable expertise and resources for this work and their continued support for N4 Pharma and Nuvec® is a clear indication of Nuvec®'s potential as a non-lipid, non-viral vaccine delivery technology and an example of how we can establish separate agreements for different versions of the Nuvec® platform technology.\" \n \nAbout the Innovate grant\n \nThe grant was provided from Innovate UK's Medicines Manufacturing Round 1: Challenge Fund, which itself is funded through the UK Government's £70m Industrial Strategy Challenge Fund to speed up the development of new medicines. It was provided to enable N4 Pharma to develop manufacturing methods for Nuvec® particles loaded with therapeutic pDNA/mRNA encoding antigens and to demonst...